1
|
Dubuisson A, Fahrner JE, Goubet AG, Terrisse S, Voisin N, Bayard C, Lofek S, Drubay D, Bredel D, Mouraud S, Susini S, Cogdill A, Rebuffet L, Ballot E, Jacquelot N, Thomas de Montpreville V, Casiraghi O, Radulescu C, Ferlicot S, Figueroa DJ, Yadavilli S, Waight JD, Ballas M, Hoos A, Condamine T, Parier B, Gaudillat C, Routy B, Ghiringhelli F, Derosa L, Breuskin I, Rouanne M, André F, Lebacle C, Baumert H, Wislez M, Fadel E, Cremer I, Albiges L, Geoerger B, Scoazec JY, Loriot Y, Kroemer G, Marabelle A, Bonvalet M, Zitvogel L. Immunodynamics of explanted human tumors for immuno-oncology. EMBO Mol Med 2020; 13:e12850. [PMID: 33372722 PMCID: PMC7799366 DOI: 10.15252/emmm.202012850] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 10/26/2020] [Accepted: 10/28/2020] [Indexed: 01/10/2023] Open
Abstract
Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.
Collapse
Affiliation(s)
- Agathe Dubuisson
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Jean-Eudes Fahrner
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.,Transgene S.A, Illkirch-Graffenstaden, France
| | - Anne-Gaëlle Goubet
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Safae Terrisse
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Nicolas Voisin
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Charles Bayard
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Sebastien Lofek
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Damien Drubay
- Institut Gustave Roussy, Villejuif, France.,Service de Biostatistique et d'epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Oncostat U1018, Inserm, Université Paris-Saclay, Équipe Labellisée Ligue Contre le Cancer, Villejuif, France
| | - Delphine Bredel
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Séverine Mouraud
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Sandrine Susini
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Alexandria Cogdill
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.,The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lucas Rebuffet
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France
| | - Elise Ballot
- Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Centre de Recherche INSERM LNC-UMR1231, Dijon, France
| | - Nicolas Jacquelot
- Institut Gustave Roussy, Villejuif, France.,Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
| | | | - Odile Casiraghi
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Camélia Radulescu
- Service d'Anatomie et cytologie pathologiques, Hôpital Foch, Suresnes, France
| | - Sophie Ferlicot
- Service d'Anatomie et cytologie pathologiques, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | | | - Marc Ballas
- Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA
| | - Axel Hoos
- Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA
| | | | - Bastien Parier
- Service de Chirurgie urologique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | - Bertrand Routy
- Division of Oncology, Department of Medicine, Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.,Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - François Ghiringhelli
- Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Lisa Derosa
- Institut Gustave Roussy, Villejuif, France.,Departement de Médicine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France
| | - Ingrid Breuskin
- Département de Chirurgie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Mathieu Rouanne
- Institut Gustave Roussy, Villejuif, France.,Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France.,Service d'Urologie, Hôpital Foch, Suresnes, France.,UVSQ - Université Paris Saclay, Versailles, France
| | - Fabrice André
- Institut Gustave Roussy, Villejuif, France.,Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Cédric Lebacle
- Service de Chirurgie urologique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | | | - Marie Wislez
- AP-HP, Centre - Université de Paris, Hôpital Cochin, Unité d'Oncologie Thoracique, Service de Pneumologie, Paris, France.,AP-HP, Hôpitaux Universitaires de l'Est Parisien, Hôpital Tenon, Service de Pneumologie, Paris, France
| | - Elie Fadel
- Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Isabelle Cremer
- Team Inflammation, Complement and Cancer, INSERM, Centre de Recherche des Cordeliers, Paris, France.,Sorbonne Université, Paris, France
| | - Laurence Albiges
- Institut Gustave Roussy, Villejuif, France.,Departement de Médicine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France
| | - Birgit Geoerger
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France
| | - Jean-Yves Scoazec
- Institut Gustave Roussy, Villejuif, France.,Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Yohann Loriot
- Institut Gustave Roussy, Villejuif, France.,Departement de Médicine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France
| | - Guido Kroemer
- Institut Gustave Roussy, Villejuif, France.,Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.,Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.,Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.,Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.,Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
| | - Aurélien Marabelle
- Institut Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Mélodie Bonvalet
- Institut Gustave Roussy, Villejuif, France.,Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - Laurence Zitvogel
- Institut Gustave Roussy, Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.,Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| |
Collapse
|
2
|
Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, Zitvogel L. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol 2020; 11:600886. [PMID: 33381121 PMCID: PMC7768083 DOI: 10.3389/fimmu.2020.600886] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 11/09/2020] [Indexed: 12/13/2022] Open
Abstract
While colorectal cancers (CRC) are paradigmatic tumors invaded by effector memory lymphocytes, the mechanisms accounting for the relative resistance of MSI negative CRC to immunogenic cell death mediated by oxaliplatin and immune checkpoint inhibitors has remained an open conundrum. Here, we propose the viewpoint where its microenvironmental contexture could be explained -at least in part- by macroenvironmental cues constituted by the complex interplay between the epithelial barrier, its microbial ecosystem, and the local immune system. Taken together this dynamic ménage-à-trois offers novel coordinated actors of the humoral and cellular immune responses actionable to restore sensitivity to immune checkpoint inhibition. Solving this paradox involves breaking tolerance to crypt stem cells by inducing the immunogenic apoptosis of ileal cells in the context of an ileal microbiome shifted towards immunogenic bacteria using cytotoxicants. This manoeuver results in the elicitation of a productive Tfh and B cell dialogue in mesenteric lymph nodes culminating in tumor-specific memory CD8+ T cell responses sparing the normal epithelium.
Collapse
Affiliation(s)
- Marine Fidelle
- Gustave Roussy, Villejuif, France
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France
- Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
- Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
- Université Paris-Saclay, Gustave Roussy, Villejuif, France
| | - Satoru Yonekura
- Gustave Roussy, Villejuif, France
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France
- Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
- Université Paris-Saclay, Gustave Roussy, Villejuif, France
| | - Marion Picard
- Gustave Roussy, Villejuif, France
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France
- Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
- Unit Biology and Genetics of the Bacterial Cell Wall, Institut Pasteur, Paris, France
| | - Alexandria Cogdill
- Department of Immunology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
- Department of Genomic Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
| | - Antoine Hollebecque
- Gustave Roussy, Villejuif, France
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - Maria Paula Roberti
- Gustave Roussy, Villejuif, France
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France
- Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
| | - Laurence Zitvogel
- Gustave Roussy, Villejuif, France
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France
- Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
- Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
- Université Paris-Saclay, Gustave Roussy, Villejuif, France
| |
Collapse
|
3
|
Daillère R, Routy B, Goubet AG, Cogdill A, Ferrere G, Alves-Costa Silva C, Fluckiger A, Ly P, Haddad Y, Pizzato E, Thelemaque C, Fidelle M, Mazzenga M, Roberti MP, Melenotte C, Liu P, Terrisse S, Kepp O, Kroemer G, Zitvogel L, Derosa L. Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. Oncoimmunology 2020; 9:1794423. [PMID: 32934888 PMCID: PMC7466864 DOI: 10.1080/2162402x.2020.1794423] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.
Collapse
Affiliation(s)
| | - Bertrand Routy
- Hematology-Oncology Division, Department of Medicine, Centre Hospitalier De l'Université De Montréal (CHUM), Montréal.,Centre De Recherche Du Centre Hospitalier De l'Université De Montréal (CRCHUM), Montréal, Canada
| | - Anne-Gaëlle Goubet
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Alexandria Cogdill
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Gladys Ferrere
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | | | - Aurélie Fluckiger
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Pierre Ly
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Yacine Haddad
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Eugenie Pizzato
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Cassandra Thelemaque
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Marine Fidelle
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Marine Mazzenga
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Maria Paula Roberti
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France.,Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - Cléa Melenotte
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France
| | - Peng Liu
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,INSERM, UMR1138, Centre De Recherche Des Cordeliers, Paris, France.,Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
| | - Safae Terrisse
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| | - Oliver Kepp
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,INSERM, UMR1138, Centre De Recherche Des Cordeliers, Paris, France.,Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
| | - Guido Kroemer
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,INSERM, UMR1138, Centre De Recherche Des Cordeliers, Paris, France.,Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.,Pôle De Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.,Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.,Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
| | - Laurence Zitvogel
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France.,Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.,Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.,Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China
| | - Lisa Derosa
- Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Inserm U1015, Villejuif, France
| |
Collapse
|
4
|
Boni A, Cogdill A, Udayakumar D, Njauw CNJ, Ferrone C, Lawrence D, Flaherty K, Fisher D, Tsao H, Wargo JA. Abstract 1970: Inhibition of BRAF-V600E increases melanocyte antigen expression and antigen-specific recognition in melanoma without altering T cell function. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-1970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Given the high prevalence of BRAFV600E mutations in melanoma, targeted therapy against BRAF, or its mutated form, is a promising new therapeutic approach for patients with melanoma. Preliminary evidence suggests that BRAFV600E contributes to immune escape, and that blocking its activity via MAPK pathway inhibition leads to increased expression of melanocyte differentiation antigens, supporting the potential use of combination targeted therapy and immunotherapy. However, indiscriminate MAPK pathway inhibition may have deleterious effects on the immune system and lead to T cell dysfunction.
The purpose of these studies was to explore the role of oncogenic BRAF in immune evasion by melanoma cells through its suppression of melanocyte differentiation antigens (MDAs). Furthermore, we sought to evaluate the effect of MAPK pathway inhibition on T lymphocyte function as a basis for combined targeted therapy and immunotherapy.
Melanoma cell lines were cultured with MEK inhibitors (U0126, PD0325901) or a specific inhibitor of BRAFV600E (PLX4720) and expression of MDAs was assayed at the mRNA and protein level. The level of micro-opthalmia transcription factor (MITF), a transcriptional regulator of MDAs, was also assayed. Untreated and treated melanoma cell lines were co-cultured with antigen-specific T lymphocytes (generated by transduction of lymphocytes with MART-1- and gp100-specific T cell receptors) and reactivity was measured via interferon gamma release. The effect of MAPK pathway inhibition on T lymphocyte function was analyzed by assaying fold-expansion after OKT-3 & IL-2 stimulation as well as antigen-specific interferon gamma release.
Inhibition of MAPK pathway in melanoma cell lines resulted in increased levels of MDAs which was associated with improved antigen-specific recognition by MART-1- and gp100-specific T lymphocytes. This was associated with higher intracellular levels of MITF. Treatment with MEK inhibitors resulted in impaired T lymphocyte function, as assayed by T cell expansion and antigen-specific interferon gamma release, whereas T cell function was preserved after treatment with a specific inhibitor of BRAFV600E.
These findings suggest that oncogenic BRAF contributes to immune evasion by transcriptional repression of melanocyte antigen expression through MITF, which may be reversed by targeted MAPK pathway inhibition. Selective inhibition of BRAFV600E enhances MDA expression while preserving T cell function, whereas MEK inhibition has deleterious effects on T cell function. These data have important implications for the design of clinical trials using combined targeted therapy and immunotherapy for melanoma as well as other cancers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1970.
Collapse
|